A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-15

Study Completion Date

2025-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 1, randomized, double-blind, placebo-controlled study of BMS-984923 administered orally twice daily (BID) for 28 days in participants with Parkinson's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233

Parkinson Disease

COMPLETED PHASE4

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

NCT05832775

Idiopathic Parkinson Disease

WITHDRAWN PHASE1

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

NCT01968460

Parkinson's Disease

COMPLETED PHASE2/PHASE3

Safety and Efficacy of DA-9805 for Parkinson's Disease

NCT03189563

Parkinson's Disease

COMPLETED PHASE2

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

NCT01227265

Parkinson Disease Idiopathic Parkinson Disease Idiopathic Parkinson's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This double-blind placebo-controlled study will evaluate 28 days of twice daily dosing of BMS-984923 at two dose levels in comparison to placebo in participants with early Parkinson's disease.

This research study will assess the safety and tolerability of multiple doses of BMS-984923 for the treatment of early Parkinson's disease and investigate Dopamine transporter levels in the brain measured with single photon emission computed tomography as an early marker of therapeutic response to a treatment that targets synapse restoration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind, parallel, 3-arm, placebo controlled

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Matching placebo

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

50 mg Active

50mg BID

Group Type EXPERIMENTAL

BMS-9894923

Intervention Type DRUG

50 mg capsules, oral administration

100mg Active

100mg BID

Group Type EXPERIMENTAL

BMS-9894923

Intervention Type DRUG

50 mg capsules, oral administration

Matching Placebo

50 and 100 mg matching placebo

Group Type PLACEBO_COMPARATOR

BMS-9894923

Intervention Type DRUG

50 mg capsules, oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BMS-9894923

50 mg capsules, oral administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ALX-001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men or women between the ages of 50 and 80 years, inclusive at the time of screening.
2. Clinical diagnosis of Parkinson's disease as defined by the United Kingdom Parkinson's disease (PD) Society Brain Bank Clinical Diagnostic Criteria and Movement Disorder Society Parkinson's disease Criteria (must meet both criteria); must include bradykinesia and responsiveness to levodopa.
3. Maintenance on stable Parkinson's disease therapy for at least 28 days prior to Screening/Visit 1 through treatment period to Day 42, with demonstratable medication efficacy as assessed by the Investigator.
4. Severity of Parkinson's disease symptoms assessed by Hoehn and Yahr Staging score ≤3.0 (assessed in the "ON" state).
5. Maintenance on permitted stable non-Parkinson's disease therapy for at least 28 days prior to Day 1 through the treatment period to Day 42.
6. Female participants of childbearing potential must have a negative urine pregnancy test at Screening and baseline, as well as be non-lactating and must agree to use a highly effective method of contraception during the study and for 30 days following last dose of study drug.
7. Male participants must be sterile or sexually inactive or agree not to father a child during the study and for 1 month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subjects must adopt a highly effective method of contraception
8. Adequate visual, hearing, cognitive and physical ability and willingness to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study
9. Institutional Review Board/Ethics Committee-approved consent form signed and dated by the participant

Exclusion Criteria

1. Diagnosis of secondary or atypical parkinsonism
2. Severe or disabling fluctuations or dyskinesias that would, in the opinion of the Investigator, interfere with completion of the study
3. Previous surgical procedure for Parkinson's disease (e.g. Duopa, deep brain stimulation)
4. Clinically significant cognitive impairment with a Montreal Cognitive Assessment score \<18
5. Has a history or current evidence of long QT syndrome
6. Has bradycardia or tachycardia on the electrocardiogram (ECG) at Screening
7. Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than Parkinson's disease, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Jacob-Creutzfeld Disease, Down's syndrome, amyotrophic lateral sclerosis, seizure disorder, or other infectious, metabolic or systemic disease affecting the central nervous system including but not limited to, syphilis, present hypothyroidism, present vitamin B12 deficiency, or other laboratory abnormalities
8. Suicidality, defined as active suicidal thoughts or ideation or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide
9. Currently active major depression as determined by Beck Depression Inventory (BDI)-II score of \>19
10. Has a history or current diagnosis of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders.
11. Clinically significant or unstable medical condition, including uncontrolled hypertension, or significant cardiac, pulmonary, hepatic, endocrine, or other systemic disease that in the Investigator's opinion may either put the participant at risk because of participation in the study, or influence the results, or impair the participant's ability to participate in the study
12. Any disorder that could interfere with absorption, distribution, metabolism or excretion of drugs (e.g., small bowel disease, Crohn's disease, celiac disease or liver disease)
13. Hospitalization or change of chronic concomitant medication within 8 weeks prior to baseline
14. Body mass index (BMI) \>38 kg/m2 or body weight \<50 kg
15. Has uncontrolled type 1 or type 2 diabetes. A subject with glycated hemoglobin (HbA1c) levels up to 7.5% can be enrolled if the Investigator believes the participant's diabetes is under control.
16. Has moderate or severe renal disease.
17. Has cancer or has had a malignant tumor (cerebral or systemic) within the past 3 years. (Participants with stable untreated prostate cancer or treated cutaneous squamous or basal cell carcinomas are not excluded)
18. Presence or history of psychosis, including if induced by anti-parkinsonian medications at doses required to improve motor symptoms, or hallucinations not induced by medications
19. Participant is currently pregnant, breast-feeding and/or lactating.
20. History of alcohol or substance abuse or dependence within the past 2 years.
21. Suspected or known allergy to any components of the study medication; Hypromellose Sodium lauryl sulfate, Lactose monohydrate, Croscarmellose sodium, Magnesium stearate.
22. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study
23. Use of anticoagulants within 30 days or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the study
24. Use of another investigational agent within 90 days or 5 half-lives (whichever is greater) prior to Screening and for the duration of the study
25. Neutropenia defined as absolute neutrophil count of \<1,500/microliter
26. Thrombocytopenia defined as platelet count \<100,000/microliter
27. Clinically significant abnormalities in screening laboratory tests, including aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine.
28. Male participants with female partners of child-bearing potential who are unwilling or unable to adhere to contraception requirements specified in the protocol.
29. Use of medications with potential drug-drug interactions within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the study
30. Any contraindication to DaTscan, including claustrophobia, the presence of metal (ferromagnetic) implants, a cardiac pacemaker, or allergy to iodine
31. History of a seizure disorder, if stable on medication is acceptable
32. An immediate family member (i.e., spouse, parent, child, or sibling, whether biological or legally adopted) of the Investigator, Sponsor or contract research organizations conducting the trial
33. History of Covid-19 infection within 6 weeks prior to screening. Participants with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with cognitive assessments, based on the Investigator's clinical judgment.
34. Unable to comply with the protocol procedures or any significant issue raised by the Investigator that may compromise participant safety or potentially interfere with study interpretation.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No